www.oncotarget.com Oncotarget, 2020, Vol. 11, (No. 3), pp: 216-236 Research Paper A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib Wayne D. Blosser1, Jack A. Dempsey1, Ann M. McNulty1, Xi Rao1, Philip J. Ebert1, Caitlin D. Lowery1, Philip W. Iversen1, Yue Wang Webster1, Gregory P. Donoho1, Xueqian Gong1, Farhana F. Merzoug1, Sean Buchanan1, Karsten Boehnke2, Chunping Yu3, Xin Tian You3, Richard P. Beckmann1, Wenjuan Wu1, Samuel C. McNeely1, Aimee Bence Lin1 and Ricardo Martinez1 1Eli Lilly and Company, Indianapolis, IN, USA 2Eli Lilly and Company, New York, NY, USA 3Eli Lilly and Company, Shanghai, China Correspondence to: Ricardo Martinez, email:
[email protected] Keywords: CHK1; prexasertib; replication stress; replication fork; innate immunity Received: September 19, 2019 Accepted: December 02, 2019 Published: January 21, 2020 Copyright: Blosser et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT The combined influence of oncogenic drivers, genomic instability, and/or DNA damage repair deficiencies increases replication stress in cancer. Cells with high replication stress rely on the upregulation of checkpoints like those governed by CHK1 for survival. Previous studies of the CHK1 inhibitor prexasertib demonstrated activity across multiple cancer types. Therefore, we sought to (1) identify markers of prexasertib sensitivity and (2) define the molecular mechanism(s) of intrinsic and acquired resistance using preclinical models representing multiple tumor types.